U.S. senator wants to know how the FDA will enforce drug ad regulations after letting go numerous workers from the office ...

As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities ...

Discover the key biotech trends moving the industry forward in Europe at a time when there lies uncertainty in global ...

One of the longstanding challenges in chemical biology has been finding ways to directly observe biological processes at work ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

Story March 6 - Atea Pharmaceuticals: After giving up on its COVID ambitions last year, Atea revealed in its annual financial results that during the first quarter of 2025, the biotech has slashed ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

For pharmaceutical and biotech companies, this is a significant development and means that a broader pool of data could become accessible for research and development purposes. It should also ...